Join to View Full Profile
44 Binney StBoston, MA 02115
Phone+1 617-632-3779
Dr. Beroukhim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2006
University of California (San Francisco)Residency, Internal Medicine, 2000 - 2003- University of California San Francisco School of MedicineClass of 2000
Certifications & Licensure
MA State Medical License 2002 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Publications & Presentations
PubMed
- Clinical, molecular and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Aleksandra B Lasica, Zhou Lan, Julie J Miller, Albert Jiao, Ian Pan
Neuro-Oncology. 2025-05-29 - Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.Kenny K H Yu, Sreyashi Basu, Gerard Baquer, Ryuhjin Ahn, Jennifer Gantchev
Nature Communications. 2025-04-28 - Effective targeting of PDGFRA-altered high-grade glioma with avapritinib.Lisa Mayr, Sina Neyazi, Kallen Schwark, Maria Trissal, Alexander Beck
Cancer Cell. 2025-04-14
Journal Articles
- PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial CarcinomaRameen Beroukhim, William J Gibson, Clinical Cancer Research
- Author Correction: Targeting Wild-Type KRAS-Amplified Gastroesophageal Cancer Through Combined MEK and SHP2 InhibitionDaniel Catenacci, Adam J Bass, Shaunt Fereshetian, Rameen Beroukhim, Nature
- Genetic and Transcriptional Evolution Alters Cancer Cell Line Drug ResponseTodd R Golub, Rameen Beroukhim, Pratiti Bandopadhayay, Nature
- Join now to see all
Press Mentions
EMBARGOED: Study Reveals Activity of Navtemadlin in Glioblastoma, Points to Possible Treatment ImprovementsFebruary 19th, 2025- Everything ChangesMay 27th, 2020
- Study Eyes Partially Lost Essential Genes as Possible Targets in CancerMay 25th, 2020
- Join now to see all
Grant Support
- Synthetic lethalities to cell cycle disruption in gliomaDANA-FARBER CANCER INST2022–2027
- Center for the Comprehensive Analysis of Cancer Somatic Copy-Number Alterations, Rearrangements, and Long-Read Sequencing DataBROAD INSTITUTE, INC.2021–2026
- Evolution of gliomas during treatment and resistanceDANA-FARBER CANCER INST2015–2026
- Evolution of gliomas during treatment and resistanceDANA-FARBER CANCER INST2015–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
